Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.98 USD | +0.92% | -12.75% | +53.25% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Evolution of the average Target Price on Spyre Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Spyre Therapeutics, Inc.
Wells Fargo Securities | |
Baird | |
Stifel Nicolaus | |
BTIG | |
Jefferies & Co. | |
LifeSci Capital | |
JonesTrading Institutional Services | |
Piper Sandler | |
Needham & Co. | |
HC Wainwright |
EPS Revisions
- Stock Market
- Equities
- SYRE Stock
- Consensus Spyre Therapeutics, Inc.